By Adam Clark
Masimo shares were surging early on Tuesday following a report that the medical-devices company is close to being acquired by Danaher.
Danaher is nearing a deal to buy Masimo at a valuation of around $9.9 billion, the Financial Times reported, citing sources familiar with the matter. Masimo closed with a market capitalization of $6.99 billion on Friday.
Masimo and Danaher didn't immediately respond to requests for comment from Barron's early on Tuesday. Masimo shares were up 33% at $173.00 in premarket trading Tuesday.
Masimo is perhaps best known for its yearslong dispute with Apple over whether the iPhone maker had infringed on the company's blood-oxygen sensor patents. The companies are still battling in various courts.
In preliminary results last month, Masimo said its 2025 revenue came to $1.52 billion, up 9% from the previous year. Shares have fallen 28% over the past 12 months through to Friday's close.
Danaher is a maker of tools and equipment for the biotechnology, life sciences, and diagnostic industries. The company was a Barron's stock pick in January, arguing that the company had the financial firepower to restart mergers-and-acquisitions activity which could boost growth.
Danaher shares were down 4.6% in premarket trading. The stock had dropped 7.1% this year so far through to Friday's close.
Write to Adam Clark at adam.clark@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 17, 2026 05:39 ET (10:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.